New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 15, 2014
09:02 EDTACT, FRXActavis has reached attractive entry point, says RBC Capital
After meeting with Actavis' (ACT) management, RBC Capital thinks there are several reasons to feel good about the company's near-term outlook. The firm adds that investors will better appreciate the strategic value in the Actavis and Forest Labs (FRX) platform over time, while Actavis' management spent a great deal of time talking about M&A. The firm keeps a Top Pick and $259 price target on Actavis.
News For ACT;FRX From The Last 14 Days
Check below for free stories on ACT;FRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
10:02 EDTACTOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:10 EDTACTDeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Subscribe for More Information
July 22, 2014
16:09 EDTACTActavis initiated with a Buy at Deutsche Bank
Subscribe for More Information
July 21, 2014
16:36 EDTACTActavis and Medicines360 announce FDA acceptance of Levosert NDA
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use